MBP-426 is an oxaliplatin-loaded liposome that is coupled to transferrin for tumor targeting.248 A phase I study (ClinicalTrials.gov Identifier: NCT00355888) in 39 patients with advanced or metastatic solid tumors showed that MBP-426 had a favorable safety profile and a dose of 226 mg/m2 was recommended for phase II trials. The gene discussed is TF; the disease is neoplasm.